Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]UCB-2897 PET Imaging in Parkinson's and MSA
NCT05274568Phase 1Completed
- Sponsor
- Invicro
- Start
- Jan 2022
- Primary completion
- Oct 2023
- Modality
- Radiopharmaceutical, Diagnostic Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [18F]UCB-2897 in Parkinson's disease (PD) and multiple system atrophy (MSA), sponsored by Invicro. Primary endpoints: Quantitative analysis of [18F]UCB-2897 brain PET scans at Day 1, Whole-body Biodistribution Outcome Measures at Day 1 and 1 more. Started Jan 2022; status: completed.
02
Drugs
[18F]UCB-2897
03
Conditions
Parkinson's disease (PD)multiple system atrophy (MSA)
Beyond the preview
Go deeper on NCT05274568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05274568.